RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Oral ONC201 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Oral ONC201

First Posted Date: 2014-09-26

Last Posted Date: 2019-05-22

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 58

Registration Number: NCT02250781

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease

Not Applicable

Terminated

Conditions: Graft Versus Host Disease

Interventions: Drug: romidepsin
Other: laboratory biomarker analysis

First Posted Date: 2014-07-30

Last Posted Date: 2017-03-30

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 1

Registration Number: NCT02203578

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

Phase 2

Terminated

Conditions: Vitiligo

Interventions: Procedure: Needling
Drug: Triamcinolone

First Posted Date: 2014-07-16

Last Posted Date: 2017-07-25

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 22

Registration Number: NCT02191748

Locations: 🇺🇸
RWJUH Dermatology office, Somerset, New Jersey, United States

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

Not Applicable

Terminated

Conditions: Stage III Verrucous Carcinoma of the Larynx
Stage IVB Squamous Cell Carcinoma of the Oropharynx
Stage IVB Verrucous Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Hypopharynx
Tongue Cancer
Stage IVA Verrucous Carcinoma of the Larynx
Stage IVB Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage IVA Squamous Cell Carcinoma of the Larynx
Stage IVA Squamous Cell Carcinoma of the Oropharynx

Interventions: Biological: cetuximab
Drug: cisplatin
Radiation: external beam radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2014-06-30

Last Posted Date: 2021-04-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 8

Registration Number: NCT02177838

Locations: 🇺🇸
New Jersey Medical School, Newark, New Jersey, United States

Novel Psychosocial Influences on Smoking Cessation

Completed

Conditions: Smoking

Interventions: Other: Tobacco Dependence Treatment

First Posted Date: 2014-06-25

Last Posted Date: 2015-05-04

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 61

Registration Number: NCT02173938

Locations: 🇺🇸
Tobacco Dependence Program, Rutgers University, New Brunswick, New Jersey, United States

Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Not Applicable

Completed

Conditions: Graft Versus Host Disease

Interventions: Dietary Supplement: Lactobacillus rhamnosus GG
Other: laboratory biomarker analysis was not performed because of no differences in the clinical outcomes

First Posted Date: 2014-05-22

Last Posted Date: 2021-04-27

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 33

Registration Number: NCT02144701

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia in Remission
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: choline magnesium trisalicylate
Drug: cytarabine
Drug: idarubicin
Other: laboratory biomarker analysis

First Posted Date: 2014-05-22

Last Posted Date: 2021-08-24

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 27

Registration Number: NCT02144675

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Phase 1

Withdrawn

Conditions: Endometrial Cancer
Recurrent Endometrial Cancer
Recurrent Ovarian Cancer
Ovarian Cancer

Interventions: Drug: BKM120
Drug: Nabpaclitaxel

First Posted Date: 2014-04-21

Last Posted Date: 2022-07-28

Lead Sponsor: Rutgers, The State University of New Jersey

Registration Number: NCT02117817

Tegaderm and Visual Evoked Potentials

Terminated

Conditions: Tumor of Pituitary and Suprasellar Region

First Posted Date: 2014-04-07

Last Posted Date: 2015-03-11

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 6

Registration Number: NCT02105337

Locations: 🇺🇸
University Hospital, Newark, New Jersey, United States

AML Therapy With Irradiated Allogeneic Cells

Not Applicable

Terminated

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Erythroleukemia (M6a)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)

Interventions: Drug: fludarabine phosphate
Drug: cytarabine
Biological: donor lymphocytes
Other: laboratory biomarker analysis
Drug: G-CSF

First Posted Date: 2014-04-07

Last Posted Date: 2021-08-24

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 6

Registration Number: NCT02105116

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Home Terms & Conditions Privacy Policy